These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22253467)

  • 1. Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer.
    Mullins CD; Montgomery R; Abernethy AP; Hussain A; Pearson SD; Tunis S;
    J Clin Oncol; 2012 Feb; 30(6):661-6. PubMed ID: 22253467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uncertainty in assessing value of oncology treatments.
    Mullins CD; Montgomery R; Tunis S
    Oncologist; 2010; 15 Suppl 1():58-64. PubMed ID: 20237219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement for cancer treatment: coverage of off-label drug indications.
    American Society of Clinical Oncology
    J Clin Oncol; 2006 Jul; 24(19):3206-8. PubMed ID: 16717290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodological recommendations for comparative research on the treatment of chronic wounds.
    Sonnad SS; Goldsack JC; Mohr P; Tunis S
    J Wound Care; 2013 Sep; 22(9):470-80. PubMed ID: 24005781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers.
    Sonnad SS; Mullins CD; Whicher D; Goldsack JC; Mohr PE; Tunis SR
    Contemp Clin Trials; 2013 Nov; 36(2):356-61. PubMed ID: 23999501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications.
    Paczynski RP; Alexander GC; Chinchilli VM; Kruszewski SP
    Int J Risk Saf Med; 2012 Jan; 24(3):137-46. PubMed ID: 22936056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Company stock prices before and after public announcements related to oncology drugs.
    Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
    J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
    Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R
    J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
    Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
    Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label use reimbursement.
    Cohen J; Wilson A; Faden L
    Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.
    Talarico L; Chen G; Pazdur R
    J Clin Oncol; 2004 Nov; 22(22):4626-31. PubMed ID: 15542812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.